WallStreetZenWallStreetZen

NASDAQ: SYBX
Synlogic Inc Stock

Open Broker Account
$0.66-0.01 (-1.49%)
Updated Dec 8, 2022
SYBX Price
$0.66
Fair Value Price
$0.92
Market Cap
$46.54M
52 Week Low
$0.55
52 Week High
$2.78
P/E
-0.76x
P/B
0.46x
P/S
41.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.67M
Earnings
-$64.54M
Gross Margin
100%
Operating Margin
-3,873.77%
Profit Margin
-3,873.9%
Debt to Equity
0.28
Operating Cash Flow
-$58M
Beta
1.2
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

SYBX Overview

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; SYNB2081 to lower uric acid for the potential treatment of gout; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SYBX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SYBX ($0.66) is undervalued by 28.26% relative to our estimate of its Fair Value price of $0.92 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SYBX ($0.66) is significantly undervalued by 28.26% relative to our estimate of its Fair Value price of $0.92 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SYBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SYBX due diligence checks available for Premium users.

Be the first to know about important SYBX news, forecast changes, insider trades & much more!

SYBX News

Valuation

SYBX fair value

Fair Value of SYBX stock based on Discounted Cash Flow (DCF)
Price
$0.66
Fair Value
$0.92
Undervalued by
28.26%
SYBX ($0.66) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SYBX ($0.66) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SYBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SYBX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.76x
Industry
13.31x
Market
21.39x

SYBX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.46x
Industry
4.98x
SYBX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SYBX's financial health

Profit margin

Revenue
$678.0k
Net Income
-$17.9M
Profit Margin
-2,641.9%
SYBX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SYBX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$128.2M
Liabilities
$27.8M
Debt to equity
0.28
SYBX's short-term assets ($97.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SYBX's short-term assets ($97.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SYBX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SYBX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$15.4M
Investing
$119.0k
Financing
$51.0k
SYBX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SYBX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SYBX$46.54M-1.93%-0.76x0.46x
RFL$46.50M-2.06%-0.30x0.46x
LPTX$46.44M-2.29%-1.04x0.66x
SNSE$46.69M-1.30%-1.03x0.41x
IMUX$46.72M+2.59%-0.43x0.43x

Synlogic Stock FAQ

What is Synlogic's quote symbol?

NASDAQ: SYBX) Synlogic trades on the NASDAQ under the ticker symbol SYBX. Synlogic stock quotes can also be displayed as NASDAQ: SYBX.

If you're new to stock investing, here's how to buy Synlogic stock.

What is the 52 week high and low for Synlogic (NASDAQ: SYBX)?

(NASDAQ: SYBX) Synlogic's 52-week high was $2.78, and its 52-week low was $0.55. It is currently -76.26% from its 52-week high and 20% from its 52-week low.

How much is Synlogic stock worth today?

(NASDAQ: SYBX) Synlogic currently has 70,519,940 outstanding shares. With Synlogic stock trading at $0.66 per share, the total value of Synlogic stock (market capitalization) is $46.54M.

Synlogic stock was originally listed at a price of $49.35 in Oct 1, 2015. If you had invested in Synlogic stock at $49.35, your return over the last 7 years would have been -98.66%, for an annualized return of -46.01% (not including any dividends or dividend reinvestments).

How much is Synlogic's stock price per share?

(NASDAQ: SYBX) Synlogic stock price per share is $0.66 today (as of Dec 8, 2022).

What is Synlogic's Market Cap?

(NASDAQ: SYBX) Synlogic's market cap is $46.54M, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Synlogic's market cap is calculated by multiplying SYBX's current stock price of $0.66 by SYBX's total outstanding shares of 70,519,940.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.